The Affiliated Hospital Of Xuzhou Medical University
Clinical trials sponsored by The Affiliated Hospital Of Xuzhou Medical University, explained in plain language.
-
New cell combo aims to tame multiple sclerosis
Disease control Not yet recruitingThis early-phase study tests a new treatment for multiple sclerosis (MS) that combines an antibody (CD20 monoclonal antibody) with immune cells (NK042 cell injection). The goal is to see if the combination is safe and can reduce MS disability. About 20 adults with relapsing or pr…
Phase: EARLY_PHASE1 • Sponsor: The Affiliated Hospital of Xuzhou Medical University • Aim: Disease control
Last updated May 26, 2026 05:30 UTC
-
Engineered immune cells take aim at lupus and muscle disease
Disease control Not yet recruitingThis early-phase study tests a new treatment called QT-019C, which uses specially engineered immune cells (CAR T-cells) from a donor to target and attack faulty cells in people with severe lupus or inflammatory myopathy that hasn't responded to standard therapies. The main goals …
Phase: EARLY_PHASE1 • Sponsor: The Affiliated Hospital of Xuzhou Medical University • Aim: Disease control
Last updated May 26, 2026 04:35 UTC
-
Heart attack drug trial aims to prevent future cardiac events
Disease control Not yet recruitingThis study tests whether the drug tafolecimab, given before a procedure to open blocked heart arteries, can lower the risk of major heart problems over one year in people who have had a heart attack. About 1,160 adults aged 18-75 will receive either the drug or standard care alon…
Phase: PHASE4 • Sponsor: The Affiliated Hospital of Xuzhou Medical University • Aim: Disease control
Last updated May 20, 2026 11:56 UTC